Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S.
Bilici A, et al.
J Cancer Res Clin Oncol. 2023 Sep;149(11):8243-8253. doi: 10.1007/s00432-023-04766-3. Epub 2023 Apr 17.
J Cancer Res Clin Oncol. 2023.
PMID: 37067546
Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], s …
Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with fur …